Omar Nadeem, MD

Articles by Omar Nadeem, MD

Assessing CAR T-Cell Therapy With Novel Targets for R/R Multiple Myeloma

July 28th 2024

Omar Nadeem, MD, clinical director, Myeloma Cellular Therapies, Dana-Farber Cancer Institute, discussed GPRC5D-targeted CAR-T, BMS-986393.

Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma

ByOmar Nadeem, MD

June 14th 2024

The medical oncologist and clinical director of Myeloma Cellular Therapies at Dana-Farber Cancer Institute emphasized promising safety in patients with high-risk disease.

Novel Therapies in Heavily Pretreated Multiple Myeloma: Omar Nadeem, MD

ByOmar Nadeem, MD

July 22nd 2021

The physician from the Dana-Farber Cancer Institute discussed the uptake of novel therapies in heavily pretreated multiple myeloma.

Omar Nadeem, MD

Articles by Omar Nadeem, MD

Assessing CAR T-Cell Therapy With Novel Targets for R/R Multiple Myeloma

Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma

Novel Therapies in Heavily Pretreated Multiple Myeloma: Omar Nadeem, MD

Latest Updated Articles

Trending on CGTlive®

Around the Helix: Cell and Gene Therapy Company Updates – November 5, 2025

What Were the Most Significant Inflection Points or Breakthroughs in Cell and Gene Therapy?

Guess the Therapy Answer November 5, 2025